Briefing
Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.
At a median follow-up of 76 months, ctDNA detection was associated with relapse (HR undefined, P<0.0001) and shorter OS (P<0.0001), with a median lead time of 12.5 months (range 1-60). MRD was identified in 10/10 patients who relapsed (median 18.5 PPM at first detection). None of 58 patients who remained ctDNA-undetected relapsed. Of patients undetected at the post-surgical landmark, 31/33 (94%) did not relapse. Forty percent of all detections were below 100 PPM.
- n: 76 patients with early breast cancer (23 TNBC, 33 HER2-positive, 16 HR-positive, 4 unknown); 598 plasma samples
- Assay: NeXT Personal (Personalis), tumor-informed whole-genome personalized panels of up to about 1,800 variants